Verrica Pharmaceuticals share price logo

Verrica Pharmaceuticals

NASDAQ: VRCA

$3.57

-0.26

(-6.79%)

Live

as on

Verrica Pharmaceuticals Stock Performance

as on October 24, 2026 at 6:11 am IST

  • Day's Low

    Day's High

    $3.40
    $3.75
    downward going graph

    4.76%

    Downside

    5.04%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.28
    $9.82
    downward going graph

    8.12%

    Downside

    175.10%

    Upside

    downward going graph

Verrica Pharmaceuticals share price movements today

Previous Close
$3.83
Open
$3.75
Volume
113.1K
Market Cap
$62.4M
Day's Low - High
$3.40 - $3.75
52 Week Low - High
$3.28 - $9.82

Verrica Pharmaceuticals Historical Returns

1 Month Return
-17.1 %
3 Month Return
-29.6 %
1 Year Return
-3.04 %
3 Year Return
-89.18 %
5 Year Return
-97 %

Verrica Pharmaceuticals Stock Fundamentals & Key Indicators

Check Verrica Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$62.4M

EPS (TTM)

-1.74

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.09

Industry PE ratio

-3.14

PEG Ratio

-0.06

EBITDA

-26.7M

Revenue (TTM)

30.3M

Profit Margin

85.89%

Return On Equity TTM

-444.44%

Verrica Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Verrica Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Verrica Pharmaceuticals image
Verrica Pharmaceuticals
Buy$62.4M-97.00%-2.0985.89%0.00%
Moderna image
Moderna
Neutral$98.1B-37.95%-30.80-12.57%0.00%
BeOne Medicines image
BeOne Medicines
StrongBuy$44.0BNA27.4787.82%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$132.9B191.61%30.2886.04%0.00%
Regeneron image
Regeneron
Buy$83.1B43.11%19.2484.86%0.46%

Stock Returns calculator for Verrica Pharmaceuticals Stock including INR - Dollar returns

The Verrica Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Verrica Pharmaceuticals investment value today

Current value as on today

₹97,753

Returns

-₹2,247

(-2.25%)

Returns from Verrica Pharmaceuticals Stock

-₹9,620 (-9.62%)

Dollar Impact

₹7,373 (+7.37%)

Analyst Recommendation on Verrica Pharmaceuticals Stock

Based on 3 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 3 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Verrica Pharmaceuticals. Average target price of $13.83

Verrica Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Verrica Pharmaceuticals.

What analysts predicted

74.19%UPSIDE

Target Price

$13.83

Current Price

$3.57

Analyzed by

3 Analysts

High

$12

Target

$13.83

Low

$9

Verrica Pharmaceuticals target price $13.83, a slight upside of 74.19% compared to current price of $3.57. According to 3 analysts rating.

Indian Investors' Interest in Verrica Pharmaceuticals Stock

Search interest for Verrica Pharmaceuticals Stock has increased by 33% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:33% versus previous 30 day period

Verrica Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
3
5
-1
0
3
12
14
5
5
5
Gross Profit
2
4
-2
0
3
12
13
3
4
4
Operating Income
-18
-15
-20
-11
-8
1
1
-6
-9
-13
EBITDA
-17
-14
-20
-13
-7
2
2
-6
-9
-12
Interest Expense
2
2
2
2
2
2
2
1
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-20
-17
-22
-16
-9
0
0
-8
-9
-13
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-20
-17
-22
-16
-9
0
0
-8
-9
-13
Net Profit Margin
70.26%
89.53%
124.42%
-81.69%
87.70%
96.11%
92.27%
72.49%
82.30%
85.02%

Verrica Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
-
12
9
5
7
35
Gross Profit
-
0
0
0
11
8
4
4
32
Operating Income
-4
-21
-30
-40
-30
-21
-65
-65
-11
EBITDA
-
-20
-27
-39
-30
-21
-62
-65
-9
Interest Expense
0
-
-
3
4
2
3
9
7
Depreciation
4
0
0
0
0
0
0
1
0
Income Before Tax
-4
-20
-28
-42
-35
-24
-66
-76
-17
Income Tax Expense
-
-
-
-
-
-
-
-
-
Net Income
-4
-20
-28
-45
-35
-24
-66
-76
-17
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
96.07%
91.97%
85.44%
63.79%
90.33%

Verrica Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-20
-17
-22
-16
-9
0
0
-8
-9
-13
Operating Cash Flow
-19
-16
-8
-16
-12
-10
9
-4
-9
-9
Investing Cash Flow
-
0
0
0
-
-
-
-
-
-
Financing Cash Flow
0
0
0
39
-4
-4
-3
13
0
0
Change in Cash
-20
-17
-8
23
-16
-14
5
9
-9
-9

Verrica Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-4
-20
-28
-42
-35
-24
-66
-76
-17
Operating Cash Flow
-4
-17
-27
-30
-27
-18
-38
-60
-17
Investing Cash Flow
-
-79
25
-3
0
54
0
0
-
Financing Cash Flow
12
99
0
35
33
-16
74
37
1
Change in Cash
8
1
-1
1
5
18
35
-23
-16

Global Institutional Holdings in Verrica Pharmaceuticals

Check out the Institutions with significant holdings in Verrica Pharmaceuticals.

Funds
Holdings
Vanguard
2.05%
VANGUARD INDEX FUNDS
1.10%
TIAA-CREF Funds
0.55%
Fidelity Concord Street Trust
0.34%
iShares
0.18%
See all

Insights on Verrica Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 5.02M → 5.86M (in $), with an average increase of 14.3% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 671.9% return, outperforming this stock by 674.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 157.7% return, outperforming this stock by 246.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 years, VRCA stock has moved down by -89.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 5 quarters, 204.0K → -13.15M (in $), with an average decrease of 784.2% per quarter

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
OrganisationVerrica Pharmaceuticals
Headquarters44 West Gay Street Suite 400, West Chester, PA, 19380, US
IndustryBiotechnology
CEOJayson Rieger

Key Management of Verrica Pharmaceuticals

Name

Title

Mr. Chris Chapman

Chief Commercial Officer

Dr. Jayson M. Rieger M.B.A., Ph.D.

President, CEO & Director

Mr. John J. Kirby CPA

Interim Chief Financial Officer

Dr. Noah L. Rosenberg M.D.

Chief Medical Officer

Mr. David Zawitz

COO, Chief Legal Officer & Secretary

Mr. Eugene Scavola

Executive Vice President of Technical Operations

Dr. Bradley J. Catalone MBA, Ph.D.

Head of Drug Development

FAQs

What is Verrica Pharmaceuticals share price today?

Verrica Pharmaceuticals share price today is $3.57 as on . Verrica Pharmaceuticals share today touched a day high of $3.75 and a low of $3.40.

What is the 52 week high and 52 week low for Verrica Pharmaceuticals share?

Verrica Pharmaceuticals share touched a 52 week high of $9.82 on and a 52 week low of $3.28 on . Verrica Pharmaceuticals stock price today i.e. is trending at $3.57,which is 63.65% down from its 52 week high and 8.84% up from its 52 week low.

What is Verrica Pharmaceuticals's market capitalisation today?

Verrica Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Verrica Pharmaceuticals Stock (VRCA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Verrica Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Verrica Pharmaceuticals Stock (VRCA) from India?

Indian investors can start investing in Verrica Pharmaceuticals (VRCA) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Verrica Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Verrica Pharmaceuticals share’s latest price of $3.57 as on October 24, 2026 at 12:41 am IST, you will get 2.8011 shares of Verrica Pharmaceuticals. Learn more about fractional shares .

What are the returns that Verrica Pharmaceuticals has given to Indian investors in the last 5 years?

Verrica Pharmaceuticals stock has given -97% share price returns and 26.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?